Waypoint Bio secures USD 14.5Mln seed funding to turbocharge drug discovery
Waypoint Bio (aka “Waypoint”), a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology, recently announced $14.5 million in seed funding led by Hummingbird Ventures with participation from other institutional investors, including Recode Ventures and pre-seed lead Fifty Years. The FDA recently approved the first ever cell therapy for solid tumors, […]
